

ASX / MEDIA ANNOUNCEMENT

14 April 2020

Share Purchase Plan restriction

Respiri Limited (ASX:RSH) ("Respiri" or the "Company"), an eHealth SaaS Company supporting respiratory health management, would like to re-iterate the following restriction regarding the Share Purchase Plan (SPP) announcement on Thursday 9 April 2020.

The Company is providing its loyal shareholders with an opportunity to participate in the SPP to raise up to \$1million (before costs) by the issue of up to 18,181,819 SPP Shares, with the capacity to accept an additional \$1 million (before costs) pursuant to the Oversubscription (SPP Offer). Under the SPP Offer, each Eligible Shareholder may apply for up to \$30,000 worth of new Shares at \$0.055 per Share (Offer Price). Applications may be made in parcels of \$1,000, \$2,000, \$5,000, \$10,000, \$15,000, \$20,000, \$25,000 and \$30,000 worth of SPP Shares.

Investors should note that the Company will only be accepting Applications under the SPP Offer from Eligible Shareholders that have *not disposed* of any of their shares between the re-commencement of trading following the Opening of the SPP Offer at 6pm on 9 April 2020 and the Closing of the SPP Offer on 1 May 2020.

To further reward loyal shareholders, as per the prospectus conditions, the Board has also taken the view that in the event of any oversubscription under the SPP Offer, the Board will allocate priority to Applications from Eligible Shareholders that have increased the number of shares held during SPP Offer period.

Investors must read the full prospectus before they decide to participate in the Offer but please note that the above mentioned restriction will apply from today.

- ENDS -

For further information, investors and media please contact:

Mr Marjan Mikel
CEO & Managing Director
Respiri Limited
P: +61 408 462 873
E: marjan@respiri.co

Mr Nicholas Smedley
Executive Chairman
Respiri Limited
P: +61 447 074 160
E: nicholas@respiri.co

This ASX announcement dated 14 April 2020 has been authorised for release by the Board of Directors of Respiri Limited.

About Respiri Limited

Respiri is an e-Health SaaS company supporting respiratory health management. Its world-first technology detects wheeze, a typical symptom of asthma, COPD and respiratory disease to provide an objective measure of airway limitation. The only platform of its kind, the flagship wheezo® product employs machine learning to provide personalised feedback and education based on the user's personal health data correlated with

environmental factors, and enables the sharing of that data, anytime, anywhere with caregivers, physicians and other health care professionals.

Respiri's mission is to help improve quality of life for hundreds of millions of children and adults around the world and dramatically reduce hospital admissions and the economic burden of asthma. Respiri Limited's operations are based in Melbourne, Australia.

For additional information about Respiri and its products, please visit www.respiri.co

Forward Looking Statements

Certain statements made in this announcement are forward-looking statements. These forward looking statements are not historical facts but rather are based on Respiri current expectations, estimates and projections about the industry in which Respiri operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of Respiri, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward looking statements. Respiri cautions shareholders and prospective shareholders not to place undue reliance on these forward looking statements, which reflect the view of Respiri only as of the date of this release. The forward looking statements made in this announcement relate only to events as of the date on which the statements are made. Respiri will not undertake any obligation to release publicly any revisions or updates to these forward looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.